{"name":"Protagonist Therapeutics","slug":"protagonist","ticker":"PTGX","exchange":"NASDAQ","domain":"protagonist-inc.com","description":"Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity","hq":"Newark, CA","founded":0,"employees":"131","ceo":"Dinesh Patel","sector":"Peptide Therapeutics","stockPrice":104.54,"stockChange":0.66,"stockChangePercent":0.64,"marketCap":"$6.7B","metrics":{"revenue":74063000,"revenueGrowth":99,"grossMargin":100,"rdSpend":159290000,"netIncome":-130149000,"cash":547785984,"dividendYield":0,"peRatio":-199.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"PTG-200 patent cliff ($0.0B at risk)","drug":"PTG-200","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"PTG-300 patent cliff ($0.0B at risk)","drug":"PTG-300","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Open-label rusfertide","genericName":"Open-label rusfertide","slug":"open-label-rusfertide","indication":"Chronic kidney disease-associated anemia","status":"phase_3"}]}],"pipeline":[{"name":"Open-label rusfertide","genericName":"Open-label rusfertide","slug":"open-label-rusfertide","phase":"phase_3","mechanism":"Rusfertide is a human erythropoietin receptor agonist.","indications":["Chronic kidney disease-associated anemia"],"catalyst":""}],"recentEvents":[{"date":"2022-02-28","type":"earnings","headline":"Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"Protagonist Therapeutics reported its fourth quarter and full year 2021 financial results, with a net loss of $24.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2021-12-20","type":"deal","headline":"Protagonist Therapeutics Announces Collaboration with Janssen Pharmaceuticals to Develop PTG-300","summary":"Protagonist Therapeutics announced a collaboration with Janssen Pharmaceuticals to develop PTG-300, a peptide-based therapeutic for the treatment of inflammatory bowel disease.","drugName":"","sentiment":"positive"},{"date":"2021-08-16","type":"trial","headline":"Protagonist Therapeutics Announces Positive Topline Results from Phase 2b Clinical Trial of PTG-200","summary":"Protagonist Therapeutics announced positive topline results from a Phase 2b clinical trial of PTG-200, a peptide-based therapeutic for the treatment of Crohn's disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-30","type":"trial","source":"simplywall.st","summary":"The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following ICOTYDE’s Phase 3 Psoriasis Data Release - Learn Why - simplywall.st","headline":"The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following ICOTYDE’s Phase 3 Psoriasis Data Release - Lear","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-29","type":"pipeline","source":"simplywall.st","summary":"Assessing Protagonist Therapeutics (PTGX) Valuation After Strong 1‑Year Shareholder Return - simplywall.st","headline":"Assessing Protagonist Therapeutics (PTGX) Valuation After Strong 1‑Year Shareholder Return","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMFVnTWdFYTYxZEYxZzlSdTBzaTlEalplbGhSRkdTOGdJdFlBZDVIME56RURwMmtXTTRLQlFqM0lDTHVubGhkbW9TdFhUMURuODhDekZfSHpjUlpoZGg4TTJsOEJITExMZ00tNzEtR01hNmp0ck05MlpXREdVeEpZdVRxb2k1Y0FUb0owTWRndFVUY2gxNGEzaGhTSXNmS01wR0czUFZyQmJndw?oc=5","date":"2026-03-02","type":"regulatory","source":"The Pharma Letter","summary":"FDA grants Takeda and Protagonist’s rusfertide priority review - The Pharma Letter","headline":"FDA grants Takeda and Protagonist’s rusfertide priority review","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOY0Y0R0VwczF3NE5FTGZhNDhEWFREVHJvMm1VY0tmbmhXRFdEUlpCWDE1RU83eXVwY3BpSE9acGRRQVIxR2x0R1BobUxfZktiUzhQMk1GSlFrcHdwZ2FYLVdTbXY2dmtTdTBCM3l5Y1RrTG9XR000a21Lc2MxTVRrN1Z0Y01IVGpRajJBVEdKYmFnS2Vfc2RfeWhkZktfdUR5Rzd5NU85TU5oMWkzQ3VWcWcyY3VaeGg5N29pVTA4dzlTZjlaNlVBRk8tQXdWRlBwREFXVjFZcGZhLWRFS0lkV2ZUYlFPV0VBWkFmc0d0UmhUcmdoZUVqNkl6YXVnLXZTNE8yVHppWi00Yk9X?oc=5","date":"2026-01-22","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOUzRDMVBqZnloZlpOVmtUZzFyZU5Xc2RmZjFfNjR5bTBRMEJodnA2a2ZZc09rTTR1WWdHV3h5UFFCNEdWNTBGUmlkS2FZbk9pMEgyN3VwUTNtc2pnclBsb3VDT3lZUzJJeWJldDlyM2ZGdUJwRThIN2ZOSTZKZ3JtZTRIX2tHOGdpTmVQbFRn?oc=5","date":"2025-10-13","type":"deal","source":"Yahoo Finance","summary":"Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal - Yahoo Finance","headline":"Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPdkhublhfejdqS0FNOGFBc2dNcjJDTnM4RGxTbmhlbmk4ZWxNcmlhdVpzdEVXNndSY2dwYXVkM3RpNmNiZ3RIM2ZvdVAyWF92ZjFhN3NHYzg3V2xLd2xBVE43R1Jtd282bklOMDNrNGNTa0l3WjZvb3NZYUtUUTNIYw?oc=5","date":"2025-10-13","type":"deal","source":"Yahoo Finance","summary":"J&J in talks to acquire Protagonist Therapeutics - Yahoo Finance","headline":"J&J in talks to acquire Protagonist Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNUzF2ZWkyR2N4UTZYbXg5Q2xQZG1EU2E3YnJteWlEbFlUS3Y1LXpWUXFNdmZKY2tjbEdrbllwOWlROVY0Sm1qNURjeHZyY3ljanNNeU9iTkpYOWdCNzF1ZUxHTTFteHhuM2I4MHJXeGFTSTZkWTk0MFdlS0lmeXlJVXBSekxiN0tISGUzOG1jdWtlckp5NG5DYUROVVQ0bnl0VzlBRjdVdXllQlky?oc=5","date":"2025-10-12","type":"deal","source":"Seeking Alpha","summary":"Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make - Seeking Alpha","headline":"Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOSThFSl8ycjdwZ2RIU3F3amxIbUJKdVJvRkJ2c21zUlFoc0FNSk9mZGtKV180U1JkXzRqRXY5djBkUEcwZ3FmUXJfVTM2RklYcEZmN0xPTjd0WGZOeXhLNGRhSDB1TVBMMFhSdDdiR2ExSE16ZWt6eDctQUpfTE4waW5hUTRHT05QeFJzNnF1cEktQ191WEVCZ3c0dzhMbkVEb0J0SzBBbERKVkEzZnN3R0czQzRJc2liOFI5NXJXUVoyVmhZU0RzMzMxcEt0VnlOVF9oTA?oc=5","date":"2025-10-10","type":"deal","source":"Reuters","summary":"Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - Reuters","headline":"Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQbFFjdXhqZmVSaktjV2ZVNzBfTDZxTG83MHJfM2lYazJic0JRYk90OW9NdEEtejdkLW5QYUV1N0tYY0ZBOGdvVkF6MWxCRFFHQnhyQ1hBOVp3VVFrdVBtWkJmcnByS0JaQnp2SFpVUVhDbHJyTTFwV1pjZmN1emQ3aWdCUXpFbmlTdmNrQ3VyMzF2TVZNR2k4WFBPWXpicTVG?oc=5","date":"2025-10-10","type":"deal","source":"WSJ","summary":"Exclusive | Johnson & Johnson in Talks to Buy Protagonist Therapeutics - WSJ","headline":"Exclusive | Johnson & Johnson in Talks to Buy Protagonist Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNQnJjVDhMaUVCc0hab1g4b25mcFBSU0RKZG14T3BqWTRLVmVHd3dHVk9WaFBqdHhqNkk3ZEdQNDBERGQ2bU9TNVdGLXF2X3pqc2tmOHRXMkVrWHp1eDhuVlZFSXFYcU5aMnkwNDI0ckZfOU9jekxQTTBPTThDWVlMOVplMEtTSU0zQ2lWTVo5akdOMEstNnNyTU9Pb3IzZnBtN1NhSFpiRXVjSlFIT0RzSU40RUtlUUVZaWVKRkVLcTFlNWZYVWxj?oc=5","date":"2025-10-10","type":"pipeline","source":"Investing.com","summary":"Protagonist Therapeutics stock surges after J&J acquisition talks report - Investing.com","headline":"Protagonist Therapeutics stock surges after J&J acquisition talks report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNmFmdGQ3WF9oMERhdEVXOHpsSDk2U3VIVV90WlRvSUJTUjFfWkRpb182cTB6NmtBOF8tUjVSbTBrenJmZ2gzN0ZiOFFJNXRMNjNITEhUWDBrbVNlNXo4MUZCSi1OcjBJaDJKU0ZPclZBeVVsQzN4SFd1bVhoRGVBYzVjb0NGYXZYODRXN0d5NTI5Tk1iQWUzQUZxdlhYYzhxY1N0cWQ0RkMydXJrLWI4M1J1Z2Y2OEJqMWMw?oc=5","date":"2025-10-10","type":"deal","source":"Sahm","summary":"Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report - Sahm","headline":"Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1CUlFKa0RoenM0TFp6YldhZmlpUnNqcGFkcWFBeUNPVzR0NXJvaFBMUFZ0WmJ1RGIyQjlZdWtXd2VpeU9kbGVsNDA1QkJCVHhoRUs0eV9UdWlaYTBCTGI4QkY1ME50aTFj?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Protagonist Therapeutics (PTGX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Protagonist Therapeutics (PTGX) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"}],"patents":[{"drugName":"PTG-200","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"PTG-300","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Janssen Pharmaceuticals","AbbVie"],"therapeuticFocus":["Inflammatory Bowel Disease","Crohn's Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":46016000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":46016000},{"period":"2024-12-31","value":434433000},{"period":"2023-12-31","value":60000000},{"period":"2022-12-31","value":26581000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":159290000,"rdSpendHistory":[{"period":"2025-12-31","value":159290000},{"period":"2024-12-31","value":138128000},{"period":"2023-12-31","value":120161000},{"period":"2022-12-31","value":126215000}],"sgaSpend":44853000,"operatingIncome":-158127000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-158127000},{"period":"2024-12-31","value":252843000},{"period":"2023-12-31","value":-93652000},{"period":"2022-12-31","value":-131373000}],"netIncome":-130149000,"netIncomeHistory":[{"period":"2025-12-31","value":-130149000},{"period":"2024-12-31","value":275188000},{"period":"2023-12-31","value":-78955000},{"period":"2022-12-31","value":-127393000}],"eps":-2.05,"epsHistory":[{"period":"2025-12-31","value":-2.05},{"period":"2024-12-31","value":4.23},{"period":"2023-12-31","value":-1.39},{"period":"2022-12-31","value":-2.6}],"cash":128390000,"cashHistory":[{"period":"2025-12-31","value":128390000},{"period":"2024-12-31","value":97249000},{"period":"2023-12-31","value":186727000},{"period":"2022-12-31","value":125744000}],"totalAssets":668188000,"totalLiabilities":53481000,"totalDebt":10323000,"equity":614707000,"operatingCashflow":57671000,"operatingCashflowHistory":[{"period":"2025-12-31","value":57671000},{"period":"2024-12-31","value":184152000},{"period":"2023-12-31","value":-70236000},{"period":"2022-12-31","value":-108137000}],"capex":-1590000,"capexHistory":[{"period":"2025-12-31","value":-1590000},{"period":"2024-12-31","value":-1355000},{"period":"2023-12-31","value":-609000},{"period":"2022-12-31","value":-795000}],"freeCashflow":56081000,"dividendsPaid":null,"buybacks":null,"employees":131,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":13277000,"ebit":-3648000,"ebitda":-3241000,"period":"2026-03-31","revenue":56368000,"epsBasic":0.06,"netIncome":3783000,"rdExpense":46739000,"epsDiluted":0.05,"grossProfit":null,"operatingIncome":-3648000},{"sga":11434000,"ebit":-50355000,"ebitda":-49979000,"period":"2025-12-31","revenue":7437000,"epsBasic":-0.69,"netIncome":-44384000,"rdExpense":46358000,"epsDiluted":-0.69,"grossProfit":null,"operatingIncome":-50355000},{"sga":11130000,"ebit":-46421000,"ebitda":-46060000,"period":"2025-09-30","revenue":4712000,"epsBasic":-0.62,"netIncome":-39339000,"rdExpense":40003000,"epsDiluted":-0.62,"grossProfit":null,"operatingIncome":-46421000},{"sga":10551000,"ebit":-42041000,"ebitda":-41737000,"period":"2025-06-30","revenue":5546000,"epsBasic":-0.55,"netIncome":-34771000,"rdExpense":37036000,"epsDiluted":-0.55,"grossProfit":null,"operatingIncome":-42041000},{"sga":11738000,"ebit":-19310000,"ebitda":-19071000,"period":"2025-03-31","revenue":28321000,"epsBasic":-0.19,"netIncome":-11655000,"rdExpense":35893000,"epsDiluted":-0.19,"grossProfit":null,"operatingIncome":-19310000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":104.54,"previousClose":103.88,"fiftyTwoWeekHigh":107.84,"fiftyTwoWeekLow":43.47,"fiftyTwoWeekRange":"43.465 - 107.84","fiftyDayAverage":100.35,"twoHundredDayAverage":81.59,"beta":1.88,"enterpriseValue":6142655488,"forwardPE":-199.3,"priceToBook":10.24,"priceToSales":90.78,"enterpriseToRevenue":82.94,"enterpriseToEbitda":-43.56,"pegRatio":0,"ebitda":-141016992,"ebitdaMargin":-190.4,"freeCashflow":-77664624,"operatingCashflow":-116635000,"totalDebt":9776000,"debtToEquity":1.5,"currentRatio":17.76,"returnOnAssets":-12.4,"returnOnEquity":-17.1,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":12,"targetMeanPrice":116.75,"targetHighPrice":137,"targetLowPrice":100,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.7,"institutionHeldPercent":120.6,"sharesOutstanding":64311373,"floatShares":52684520,"sharesShort":7540996,"shortRatio":10.72,"shortPercentOfFloat":11.7,"epsTrailing":-1.81,"epsForward":-0.52,"revenuePerShare":1.16,"bookValue":10.21,"officers":[{"age":68,"name":"Dr. Dinesh V. Patel Ph.D.","title":"CEO, President, Secretary & Director"},{"age":51,"name":"Mr. Asif  Ali","title":"Executive VP & CFO"},{"age":66,"name":"Dr. Arturo M. Molina FACP, M.D., M.S.","title":"Chief Medical Officer"},{"age":null,"name":"Mr. Venkat  Thalladi Ph.D.","title":"EVP & Chief Technical Officer"},{"age":null,"name":"Dr. Newman  Yeilding M.D.","title":"Executive VP, Chief Scientific Officer"},{"age":54,"name":"Mr. Matthew M. Gosling J.D.","title":"Executive VP and Chief Legal & Business Officer"},{"age":null,"name":"Ms. Carena  Spivey","title":"Executive VP & Chief Human Resources Officer"},{"age":61,"name":"Dr. Ashok  Bhandari Ph.D.","title":"EVP & Chief Discovery Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.protagonist-inc.com","phone":"510 474 0170"}}